Your browser doesn't support javascript.
loading
First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110).
Stahler, Arndt; Modest, Dominik P; Fischer von Weikersthal, Ludwig; Kaiser, Florian; Decker, Thomas; Held, Swantje; Graeven, Ullrich; Schwaner, Ingo; Denzlinger, Claudio; Schenk, Michael; Kurreck, Annika; Heinrich, Kathrin; Gießen-Jung, Clemens; Neumann, Jens; Kirchner, Thomas; Jung, Andreas; Stintzing, Sebastian; Heinemann, Volker.
Afiliação
  • Stahler A; Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology, and Cancer Immunology, Charitéplatz 1, 10117 Berlin, Germany. Electronic address: arndt.stahler@charite.de.
  • Modest DP; Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology, and Cancer Immunology, Charitéplatz 1, 10117 Berlin, Germany; Charité - Universitätsmedizin, German Cancer Consortium (DKTK), Partner Site Berlin
  • Fischer von Weikersthal L; Klinikum St. Marien, Oncology, Amberg, Germany.
  • Kaiser F; VK&K Studien GbR, Landshut, Germany.
  • Decker T; Onkologische Praxis, Ravensburg, Germany.
  • Held S; ClinAssess GmbH, Leverkusen, Germany.
  • Graeven U; Kliniken Maria Hilf GmbH, Mönchengladbach, Germany.
  • Schwaner I; Onkologische Schwerpunktpraxis Kurfürstendamm, Berlin, Germany.
  • Denzlinger C; Marienhospital, Stuttgart, Germany.
  • Schenk M; Krankenhaus Barmherzige Brüder Regensburg, Regensburg, Germany.
  • Kurreck A; Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology, and Cancer Immunology, Charitéplatz 1, 10117 Berlin, Germany.
  • Heinrich K; Department of Medicine III, University Hospital, LMU Munich, Germany.
  • Gießen-Jung C; Department of Medicine III, University Hospital, LMU Munich, Germany.
  • Neumann J; Institute of Pathology, Faculty of Medicine, LMU Munich, Germany; LMU Munich, German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Kirchner T; Institute of Pathology, Faculty of Medicine, LMU Munich, Germany; LMU Munich, German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Jung A; Institute of Pathology, Faculty of Medicine, LMU Munich, Germany; LMU Munich, German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Stintzing S; Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology, and Cancer Immunology, Charitéplatz 1, 10117 Berlin, Germany; Charité - Universitätsmedizin, German Cancer Consortium (DKTK), Partner Site Berlin
  • Heinemann V; Department of Medicine III, University Hospital, LMU Munich, Germany; LMU Munich, German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Eur J Cancer ; 173: 194-203, 2022 09.
Article em En | MEDLINE | ID: mdl-35940054
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Retais / Neoplasias Colorretais / Neoplasias do Colo Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Retais / Neoplasias Colorretais / Neoplasias do Colo Idioma: En Ano de publicação: 2022 Tipo de documento: Article